Literature DB >> 3670565

Changes in the activity of GAD in the basal ganglia of the rat after striatal dopaminergic denervation.

J Segovia1, M Garcia-Munoz.   

Abstract

The aim of this experiment was to study the effect of a unilateral lesion of the dopamine-containing nigro-striatal pathway, on the activity of glutamic acid decarboxilase (GAD) in different structures at two survival times: 4 and 8 weeks. The structures studied were the striatum and its output target areas, globus pallidus, entopeduncular nucleus and substantia nigra. Four weeks after the lesion, GAD activity was increased in the ipsilateral striatum, globus pallidus and substantia nigra. This effect was reversed at 8 weeks, when a decrease in enzyme activity was observed. These time related changes in enzyme activity reveal the presence of a physiological compensatory process.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3670565     DOI: 10.1016/0028-3908(87)90113-4

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  4 in total

1.  Morphological changes in the rat neostriatum after unilateral 6-hydroxydopamine injections into the nigrostriatal pathway.

Authors:  C A Ingham; S H Hood; B van Maldegem; A Weenink; G W Arbuthnott
Journal:  Exp Brain Res       Date:  1993       Impact factor: 1.972

2.  Intrastriatal mesencephalic grafts affect neuronal activity in basal ganglia nuclei and their target structures in a rat model of Parkinson's disease.

Authors:  N Nakao; M Ogura; K Nakai; T Itakura
Journal:  J Neurosci       Date:  1998-03-01       Impact factor: 6.167

3.  Topographic distribution of dopamine uptake, choline uptake, choline acetyltransferase, and GABA uptake in the striata of weaver mutant mice.

Authors:  J R Simon; B Ghetti
Journal:  Neurochem Res       Date:  1992-05       Impact factor: 3.996

4.  Methylazoxymethanol (MAM)-induced brain lesion and oral dyskinesia in rats.

Authors:  P Johansson
Journal:  Psychopharmacology (Berl)       Date:  1990       Impact factor: 4.530

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.